^
Association details:
| Biomarker: | PD-L1 underexpression |
|---|---|
| Cancer: | Triple Negative Breast Cancer |
| Drug: | Tecentriq (atezolizumab) (PD-L1 inhibitor) + autogene cevumeran (RG6180) (Immunostimulant) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Abstract CT301: A phase Ib study to evaluate RO7198457, an individualized Neoantigen Specific immunoTherapy (iNeST), in combination with atezolizumab in patients with locally advanced or metastatic solid tumors
Excerpt:
...132 patients enrolled in cohorts with doses ranging from 15-50 μg RO7198457 in combination with atezolizumab….patients had low levels of PD-L1 expression (93% patients with <5% PD-L1 expression on tumor cells, 79% patients with <5% expression on immune cells)....RO7198457 in combination with atezolizumab has a manageable safety profile consistent with the mechanisms of action of the study drugs and induces significant levels of neoantigen-specific immune responses.
DOI:
10.1158/1538-7445.AM2020-CT301
